Using proton pump inhibitors (PPIs) during treatment with palbociclib (Ibrance) was linked to higher risks of progression and death among patients with breast cancer, according to a retrospective cohort study from South Korea.
Among over 1,300 women, the median clinical progression-free survival (PFS) in the group taking both a PPI and palbociclib was 25.3 months compared with 39.8 months in those who never used a PPI during palbociclib treatment (P
>>> Read full article>>>
Copyright for syndicated content belongs to the linked Source : MedPageToday – https://www.medpagetoday.com/hematologyoncology/breastcancer/105604
